Download App

Log in to access Online Inquiry
Company Overview More
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
CEO: Sommadossi Ph.D., Jean-Pierre
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

AVIR Atea Pharmaceuticals

7.250+0.110+1.54%
Close 05/19 20:00 ET
High
7.620
Open
7.140
Turnover
6.85M
Low
7.110
Pre Close
7.140
Volume
935.31K
Market Cap
603.62M
P/E(TTM)
13.94
52wk High
46.910
Shares
83.26M
P/E(Static)
5.29
52wk Low
5.310
Float Cap
500.00M
Bid/Ask %
33.33%
Historical High
94.174
Shs Float
68.97M
Volume Ratio
1.00
Historical Low
5.310
Dividend TTM
--
Div Yield TTM
--
P/B
0.89
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.36%
Amplitude
7.14%
Avg Price
7.328
Lot Size
1
Float Cap
500.00M
Bid/Ask %
33.33%
Historical High
94.174
Shs Float
68.97M
Volume Ratio
1.00
Historical Low
5.310
Dividend TTM
--
P/B
0.89
Dividend LFY
--
Turnover Ratio
1.36%
Amplitude
7.14%
Avg Price
7.328
Lot Size
1
Price Forecast

No Data

News

Comment